| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5697688 | Cancer Treatment Reviews | 2017 | 33 Pages |
Abstract
Breast cancer survivors, those treated with procarbazine or other alkylating agents and those with a higher age at diagnosis are at highest risk of diminished ovarian function. However, all studies included in this review showed methodological limitations. It is imperative that nation-wide registries guarantee long term follow-up during the adult life of cancer survivors.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Annelies Overbeek, Marleen H. van den Berg, Flora E. van Leeuwen, Gertjan J.L. Kaspers, Cornelis B. Lambalk, Eline van Dulmen-den Broeder,